

Supplementary Table S1 – Baseline demographic and clinical characteristics for propensity score matched bevacizumab MVASI biosimilar cohort for all balancing variables after propensity score matching.

		MVASI biosimilar	Originator controls	Standardized differences
		N = 633	N =2495	
Age	Mean ± SD	63.34 ± 11.6	63.37 ± 11.4	0
	Median (IQR)	64 (56-72)	64 (56-72)	0
Sex, n (%)	Female	246 (38.9)	958 (38.4)	0.1
Colorectal cancer type, n (%)	Malignant neoplasm of colon	436 (68.9)	1712 (68.6)	0.01
	Malignant neoplasm of rectosigmoid junction	55 (8.7)	219 (8.8)	0
	Malignant neoplasm of rectum	142 (22.4)	564 (22.6)	0
Chemotherapy backbone drug, n (%)	Irinotecan	516 (81.5)	2052 (82.2)	0.02
	Oxaliplatin	117 (18.5)	443 (17.8)	0.02
Prior cancer diagnosis, n (%)	Yes	65 (10.3)	267 (10.7)	0.01
Charlson Index Score, n (%)	0	346 (54.7)	1346 (53.9)	0.01
	1	70 (11.1)	293 (11.7)	0.02
	2+	35 (5.5)	162 (6.5)	0.04
	No hospitalization in look-back period	182 (28.8)	694 (27.8)	0.02
Total ACG Score	Mean ± SD	8.76 ± 3.3	8.66 ± 3.3	0.03
	Median (IQR)	9 (6-11)	9 (6-11)	0.02
LHIN, n (%)	1	57 (9)	226 (9.1)	0
	2	54 (8.5)	203 (8.1)	0.01
	3	31 (4.9)	129 (5.2)	0.01
	4	35 (5.5)	136 (5.5)	0
	5	49 (7.7)	192 (7.7)	0
	6	45 (7.1)	179 (7.2)	0
	7	67 (10.6)	250 (10)	0.02
	8	92 (14.5)	366 (14.7)	0
	9	56 (8.8)	246 (9.9)	0.03
	10	3 – 7 ^a	14 – 18 ^a	0.02
	11	64 (10.1)	256 (10.3)	0
	12	5 – 9 ^a	18 – 22 ^a	0.03
	13	62 (9.8)	241 (9.7)	0
	14	9 (1.4)	35 (1.4)	0
Neighbourhood income quintile, n(%)	1 (lowest)	124 (19.6)	473 (19)	0.02
	2	125 (19.7)	528 (21.2)	0.04
	3	129 (20.4)	499 (20)	0.01
	4	139 (22)	527 (21.1)	0.02
	5 (highest)	116 (18.3)	468 (18.8)	0.01
Rurality, n (%)	Yes	64 (10.1)	245 (9.8)	0.01
Prior colorectal surgery, n (%)	Yes	472 (74.6)	1839 (73.7)	0.02
Prior adjuvant oxaliplatin, n (%)	Yes	173 (27.3)	702 (28.1)	0.02
Prior capecitabine, n (%)	Yes	118 (18.6)	457 (18.3)	0.01

Prior fluorouracil, n (%)	Yes	305 (48.2)	1227 (49.2)	0.02
Prior radiation treatment, n (%)	Yes	153 (24.2)	580 (23.2)	0.02
Prior radiation of the rectum, n (%)	Yes	90 (14.2)	348 (13.9)	0.01

ACG, Adjusted Clinical Group; IQR, interquartile range; LHIN, local integrated health network; SD, standard deviation

^a Cell value suppressed

Supplementary Table S2 – Baseline demographic and clinical characteristics for propensity score matched bevacizumab Zirabev biosimilar cohort for all balancing variables after propensity score matching.

		Zirabev biosimilar	Originator controls	Standardized differences
		N = 112	N = 448	
Age	Mean ± SD	63.25 ± 10.8	62.87 ± 11.4	0.03
	Median (IQR)	66 (56-72)	64 (56-72)	0.03
Sex, n (%)	Female	49 (43.8)	204 (45.5)	0.04
Colorectal cancer type, n (%)	Malignant neoplasm of colon	67 (59.8)	270 (60.3)	0.01
	Malignant neoplasm of rectosigmoid junction	13 (11.6)	49 (10.9)	0.02
	Malignant neoplasm of rectum	32 (28.6)	129 (28.8)	0
Chemotherapy backbone drug, n (%)	Irinotecan	93 (83)	382 (85.3)	0.06
	Oxaliplatin	19 (17)	66 (14.7)	0.06
Prior cancer diagnosis, n (%)	Yes	12 (10.7)	56 (12.5)	0.06
Charlson Index Score, n (%)	0	64 (57.1)	245 (54.7)	0.05
	1	12 (10.7)	50 (11.2)	0.01
	2+	6 (5.4)	31 (6.9)	0.07
	No hospitalization in look-back period	30 (26.8)	122 (27.2)	0.01
Total ACG Score	Mean ± SD	8.16 ± 2.9	8.22 ± 3.3	0.02
	Median (IQR)	8 (6-10)	8 (6-11)	0.06
LHIN, n (%)	1	0 (0)	0 (0)	0
	2	1 - 5 ^a	1 - 5 ^a	0.05
	3	0 (0)	0 (0)	0
	4	48 (42.9)	180 (40.2)	0.05
	5	1 - 5 ^a	1 - 5 ^a	0.03
	6	11 (9.8)	35 (7.8)	0.07
	7	1 - 5 ^a	26 - 30 ^a	0.12
	8	3 - 7 ^a	25 - 29 ^a	0.07
	9	1 - 5 ^a	17 - 21 ^a	0.02
	10	3 - 7 ^a	15 - 19	0.03
	11	0 (0)	0 (0)	0
	12	28 (25)	122 (27.2)	0.05
	13	1 - 5 ^a	3 - 7 ^a	0.06
	14	1 - 5 ^a	10 - 14 ^a	0
Neighbourhood income quintile, n(%)	1 (lowest)	23 (20.5)	103 (23.0)	0.06
	2	25 (22.3)	106 (23.7)	0.03
	3	22 (19.6)	76 (17)	0.07
	4	20 (17.9)	79 (17.6)	0.01
	5 (highest)	22 (19.6)	84 (18.8)	0.02
Rurality, n (%)	Yes	17 (15.2)	59 (13.2)	0.06
Prior colorectal surgery, n (%)	Yes	96 (85.7)	394 (87.9)	0.07
Concurrent liver, lung, colorectal resection	Yes	22 (19.6)	83 (18.5)	0.03

Prior adjuvant oxaliplatin, n (%)	Yes	41 (36.6)	163 (36.4)	0
Prior capecitabine, n (%)	Yes	20 (17.9)	78 (17.4)	0.01
Prior fluorouracil, n (%)	Yes	71 (63.4)	278 (62.1)	0.03
Prior radiation treatment, n (%)	Yes	33 (29.5)	131 (29.2)	0
Prior radiation of the rectum, n (%)	Yes	21 (18.8)	84 (18.8)	0

ACG, Adjusted Clinical Group; IQR, interquartile range; LHIN, local integrated health network; SD, standard deviation

^a Cell value suppressed